ME00876B - 4"supstituisani-9-deokso-9a-aza-9a-homoeritromicin a derivati - Google Patents
4"supstituisani-9-deokso-9a-aza-9a-homoeritromicin a derivatiInfo
- Publication number
- ME00876B ME00876B MEP-1999-586A MEP1999586A ME00876B ME 00876 B ME00876 B ME 00876B ME P1999586 A MEP1999586 A ME P1999586A ME 00876 B ME00876 B ME 00876B
- Authority
- ME
- Montenegro
- Prior art keywords
- hydroxy
- compound according
- groups
- integer
- optionally substituted
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims 32
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 29
- -1 C 1 -C 6 alkyl Chemical group 0.000 claims 18
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 11
- 229920006395 saturated elastomer Polymers 0.000 claims 9
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 8
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 3
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 claims 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000006239 protecting group Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 2
- 241000251468 Actinopterygii Species 0.000 claims 2
- 241000271566 Aves Species 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000010362 Protozoan Infections Diseases 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000003367 polycyclic group Chemical group 0.000 claims 2
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 claims 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 claims 1
- 125000006019 1-methyl-1-propenyl group Chemical group 0.000 claims 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 claims 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- DBTDEFJAFBUGPP-UHFFFAOYSA-N Methanethial Chemical compound S=C DBTDEFJAFBUGPP-UHFFFAOYSA-N 0.000 claims 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 1
- LINDOXZENKYESA-UHFFFAOYSA-N TMG Natural products CNC(N)=NC LINDOXZENKYESA-UHFFFAOYSA-N 0.000 claims 1
- UXMAGLKOTRPVPA-UHFFFAOYSA-N [Na+].[K+].C[O-].CC[O-] Chemical compound [Na+].[K+].C[O-].CC[O-] UXMAGLKOTRPVPA-UHFFFAOYSA-N 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Chemical group C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- FATAVLOOLIRUNA-UHFFFAOYSA-N formylmethyl Chemical group [CH2]C=O FATAVLOOLIRUNA-UHFFFAOYSA-N 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- KPADFPAILITQBG-UHFFFAOYSA-N non-4-ene Chemical compound CCCCC=CCCC KPADFPAILITQBG-UHFFFAOYSA-N 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical group [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims 1
- 229910000104 sodium hydride Inorganic materials 0.000 claims 1
- 239000012312 sodium hydride Substances 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- JABYJIQOLGWMQW-UHFFFAOYSA-N undec-4-ene Chemical compound CCCCCCC=CCCC JABYJIQOLGWMQW-UHFFFAOYSA-N 0.000 claims 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
- 229920002554 vinyl polymer Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (31)
1. Jedinjenje formule ili njegova farmaceutski prihvatljiva so gde je: R1. H. hidroksi ili metoksi; R2 je hidroksi; R3 je C1-C10alkil, C2-C10alkenil. C2-C10 alkinil, cijano. -CH2S(0)nR8 gde je n ceo broj od 0 do 2, -CH2OR8, -CH2N(OR9)R8, -CH2NR8Rl5, -(CH2)m(C6-C10aril) ili -(CH2)m(5-10 člani heteroaril), gde je m ceo broj od 0 do 4 i gde su prethodno navedene R3 grupe po potrebi supstituisana sa 1 do 3, R16 grupe; ili R2 i R3 zajedno formiraju oksazolil prsten kao što je dato u dalje tekstu R4 je H, -C(0)R9, -C(0)0R9, -C(0)NR9Rl° ili hidroksi zaštitna grupa; R5 je -SR8, -(CH2)nC(0)R8, gde je n, 0 ili 1, C1-C10alkil, C2-C10alkenil, C2-C10 alkinil, -(CH2)m(C6-C10aril) ili -(CH2)m(5-10 člani heteroaril), gde je m ceo broj od 0 do 4 i gde su prethodno navedene R5 grupe po potrebi supstituisane sa 1 do 3, R16 grupe; I svaka od R6 i R7je nezavisno H, hidroksi, C1-C8alkoksi, C1-C6alkil, C2-C6 alkenil, C2-C6alkinil, -(CH2)m(C6-C10aril) ili -(CH2)m(5-10 člani heteroaril), gde je m ceo broj od 0 do 4; svaka R8 je nezavisno H, C1-C10oalkil, C2-C10alkenil, C2-C10 alkinil, -(CH2)qCRnR12(CH2)rNR13R14 gde su q i r svaki nezavisno ceo broj od 0 do 3 osim u slučaju kada q i r nisu oba 0, -(CH2)m(C6-C10aril) ili -(CH2)m(5-10 člani heteroaril), gde je m ceo broj od 0 do 4 i gde su prethodno navedene R8 grupe osim H, po potrebi supstituisane sa 1 do 3, R16 grupe; ili gde je R8, -CH2NR8R15, gde R15 i R8 mogu zajedno da formiraju 4-10-člani monociklični ili policiklični zasićen prsten ili 5-10-člani hetefoarilni prsten, gde ovi zasićeni i heteroarilni prstenovi po potrebi sadrže 1 ili 2 heteroatoma odabrana od O, S i -N(R8)- kao dodatak azotu za koji su vezane R15 i R8, pri čemu dati zasićen prsten sadrži 1 ili 2 ugljenik -ugljenik dvostruke ili trostruke veze i gde su dati zasićeni i heteroarilni prstenovi po potrebi supstituisani sa 1 do 3, R16 grupe; svaka R9 i R10 je nezavisno H ili C1-C6alkil; svaka R11, R12, R13 i R14 grupe je nezavisno odabrana od H, C1-C10alkil, -(CH2)m(C6-C10aril) ili -(CH2)m(5-10 člani heteroaril), gde je m ceo broj od 0 do 4 i gde su prethodno navedene R11, R12, R13 i R14 grupe osim H, su po potrebi supstituisane sa 1 do 3, R16 grupe; ili R11 i R13 uzeti zajedno formiraju -(CH2)p-, gde je p, ceo broj od 0 do 3 tako daje formiran 4-7 člani zasićen prsten koji po potrebi sadrži 1 ili 2 ugljenik-ugljenik dvostruke ili trostruke veze; ili R13 i R14 uzeti zajedno formiraju 4-10 člani monociklični ili policiklični zasićen prsten ili 5-10 člani heteroarilni prsten koji po potrebi sadrže 1 ili 2 heteroatoma odabrana od 0, S i -N(R8)-, pored azota za koji su vezane R13 i R14, pri čemu dati zasićeni prsten sadrži 1 ili 2 ugljenik-ugljenik dvostruke ili trostruke veze, i gde su Zasićeni i heteroarilni prstenovi po potrebi supstituisani sa 1 do 3 R16 grupe; R15 je H, C1-C10alkil, C2-C10alkenil ili C2-C10 alkinil, gde su R15 grupe po potrebi supstituisane sa 1 do 3 supstituenta nezavisno odabrana od halo i -OR9; svaka R16 je nezavisno odabrana od halo, cijano, nitro, trifluormetil, azido, -C(0)R17, -C(0)0R17, -C(0)0R17, -0C(0)R17, -NR6C(0)R1, -C(0)NR6R1, -NR6R1, hidroksi, C1-C6alkil, C1-C6alkoksi, -(CH2)m(C6-C10aril) i -(CH2)m(5-10 člani heteroaril), gde je m ceo broj od 0 do 4 i gde su navedene aril i heteroaril supstituenti po potrebi supstituisani sa 1 ili 2 supstituenta nezavisno odabrana od halo, cijano, nitro, trifluorometil, azido, -C(0)R17, -C(0)0R17, -C(0)0R17, -0C(0)0R17, -NR6C(0)R1, -C(O)NR6R1, -NR6R1, hidroksi, C1-C6alkii i C1-C6alkoksi; svaka R17 je nezavisno odabrana od H, C1-C10alkil, C2-C10alkenil, C2-C10C2-C10 alkinil, -(CH2)m(C6-C10aril) i -(CH2)m(5-10 člani heteroaril), gde je m ceo broj od 0 do 4; pod uslovom da R8 nije H, kada je R3, -CH2S(0)nR8;
2. Jedinjenje prema zahtevu 1, naznačeno time, što je R4, H, acetil ili benziloksikarbonil.
3. Jedinjenje prema zahtevu 2, naznačeno time, što je R1, hidroksi, R2 je hidroksi, a R3 je -CH2NR15R8 ili -CH2SR8.
4. Jedinjenje prema zahtevu 3, naznačeno time, stoje R3, -CH2NR15R8, a R15 i R8 su nezavisno odabrani od H, C1-C10alkil, C2-C10alkenil i C2-C10 alkinil, gde su R15 i R8 grupe, osim H, po potrebi supstituisane sa 1 ili 2 supstituenta nezavisno odabranih od hidroksi, halo i C1-6alkoksi.
5. Jedinjenje prema zahtevu 4, naznačeno time, što su R15 i R8 nezavisno odabrane od H, metil, etil, alil, n-butil, izobutil, 2-metoksietil, ciklopentil, 3-metoksipropil, 3-etoksipropil, n-propil, izopropil, 2-hidroksietil, ciklopropil, 2, 2, 2-trifluoroetil, 2-propinil, sec-butil, terc-butil i n-heksil.
6. Jedinjenje prema zahtevu 2, naznačeno time, što je Rl, hidroksi, R2 je hidroksi, R3 je -CH2NHR8 i R8 je -(CH2)m(C6-C10aril) gde je m ceo broj od 0 do 4.
7. Jedinjenje prema zahtevu 6, naznačeno time, što je R8, fenil ili benzil.
8. Jedinjenje prema zahtevu 2, naznačeno time, što je R1, hidroksi, R2 je hidroksi, R3 je -CH2NR15R8, a R15 i R8 zajedno formiraju 4-10 elani zasićeni prsten.
9. Jedinjenje prema zahtevu 8, naznačeno time, što R15 i R8 zajedno formiraju piperidino, trimetilenimino ili morfolino prsten.
10. Jedinjenje prema zahtevu 2, naznačeno time, stoje R1, hidroksi, R2 je hidroksi, R3 je -CH2NR15R8, a R15 i R8 zajedno formiraju 5-10 člani heteroarilni prsten po potrebi supstituisan sa 1 ili 2, C1-C6alkil grupe.
11. Jedinjenje prema zahtevu 10, naznačeno time, što R15 i R8 zajedno formiraju pirolidino, triazolil ili imidazolilni prsten gde su heteroarilne grupe po potrebi supstituisane sa 1 ili 2 metil grupe.
12. Jedinjenje prema zahtevu 2, naznačeno time, što je R1. hidroksi. R2 je hidroksi. R3 je -CH2SR8. a R8 odabran od C1-C10alkil, C2-C10alkenil, C2-C10 alkinil, gde su R8 grupe, po potrebi supstituisane sa 1 ili 2 supstituenta nezavisno odabranih od hidroksi, halo i C1-6alkoksi.
13. Jedinjenje prema zahtevu 12, naznačeno time. što je R8, metil, etil ili 2-hidroksietil.
14. Jedinjenje prema zahtevu 2, naznačeno time, što je R1, hidroksi, R2 je hidroksi, a R3 je odabrana od C1-C10alkil, C2-C10alkenil i C2-C10 alkinil, gde su R3 grupe po potrebi supstituisane sa 1 ili 2 supstituenta nezavisno odabrana od hidroksi, -C(0)R17, NR6R7, halo cijano, azido, 5-10 članih heteroarila i C1-C6alkoksi.
15. Jedinjenje prema zahtevu 14, naznačeno time, stoje R3, metil, alil, vinil, etinil, 1-metil-1-propenil, 3-metoksi-l-propiniI, 3-dimetilamino-l-propinil. 2-piridiletinil, 1-propinil. 3-hidroksi-l-propinil, 3-hidroksi-l-propenil, 3-hidroksipropil, 3-metoksi-l-propenil, 3-metoksipropil, l-propinil, n-butil, etil, propil, 2-hidroksietil, azidometil, formilmetil, 6-cijano-1-pentinil, 3 -dimetilamino-1 -propenil ili 3-dimetilarainopropil.
16. Jedinjenje prema zahtevu 2, naznačeno time, Što je R1, hidroksi, R2 je hidroksi, a R3 je -(CH2)m(5-10 člani heteroaril) gde je m ceo broj od 0 do 4.
17. Jedinjenje prema zahtevu 16, naznačeno time, što je R3, 2-tienil, 2-piridil, l-metil-2-imidazolil, 2-furil ili l-metil-2-pirolil.
18. Jedinjenje prema zahtevu 2, naznačeno time, što je R1, hidroksi, R2 je hidroksi, R3 je -(CH2)m(C6-C10aril) gde je m ceo broj od 0 do 4.
19. Jedinjenje prema zahtevu 18, naznačeno time, što je R3, fenil.
20. Jedinjenje prema zahtevu 2, naznačeno time, što R2 i R3 zajedno formiraju oksazolil prsten:
21. Jedinjenje prema zahtevu 2, naznačeno time, što je R3 odabrana od: gde je X3, O, S ili -N(R15)-, R9 i R15 su kao što je definsano u zahtevu 1, a -OR9 grupa može da bude vezana za bilo koji raspoloživ ugljenik na fenil grupi.
22. 11 -(4-đimetilammo-3-hidroksi-6-metil-tetrahidro-piran-2-iloksi)-2-etil-3, 4, l 0-trihidroksi-13-(5-hidroksi-4-metoksi-4, 6-dimetil)-5-propilaminometil)-tetrahidro-piran-2-iloksi) -3, 5, 8, 10, 12, 14-heksametil-1 -oksa-6-aza-ciklapentadekan-15-on.
23. Jedinjenje prema jednom od zahteva 1 do 22 za primenu kao lek.
24. Primena jedinjenja prema jednom od zahteva 1 do 22 za proizvodnju leka za lečenje bakterijskih infekcija ili infekcije izazvanih protozoama kod sisara, riba i ptica.
25. Farmaceutski preparat, naznačen time, što sadrži jedinjenje prema jednom od zahteva 1 do 22 i farmaceutski prihvatljiv nosač.
26. Preprat prema zahtevu 25, naznačeno time, što se koristi za lečenje bakterijskih infekcija ili infekcija izazvanih protozoama kod sisara, riba i ptica.
27.. Postupak za dobijanje jedinjenja formule (1) prema zahtevu 1, naznačen time, što obuhvata reakciju jedinjenja formule: gde su R1 i R4 kao što je prethodno definisano, sa jedinjenjem formule HOR8, HSR8 ili HNR15R8. gde su n, R15 i R8, kao što je prethodno definisano u zahtevu 1, tako da ukoliko se upotrebe jedinjenja formule HSR8, rezultujuća R3 grupa formule -CH2SR8 je po potrebi oksidovana u CH2S(0)R8 ili -CH2S(0)2R8.
28. Postupak prema zahtevu 27, naznačen time, što se jedinjenje formule 5 dobija tretiranjem jedinjenja formule gde su R1 i R4 kao što je definisano u zahtevu 1, sa (CH3)3S(0)nX2, gde je n, 0 ili 1 i X2 je halo, -BF4 ili PF6 u prisustvu baze.
29. Postupak prema zahtevu 28, naznačen time, što je X2, jod ili BF4, a data baza je odabrana od kalijum terc-butoksida, natrijum terc-butoksida, hatrijum etoksida, natrijum hidrida, 1, 1, 3, 3-tetrametilgvanidina, l, 8-diazabiciklo[5. 4. 0]undek-7-ena, 1, 5-diazabiciklo[4. 3. 0]non-5-ena, kalijum heksametildisilazida (KHMDS), kalijum etoksida natrijum metoksida.
30. Jedinjenje formule ili njegova farmaceutski prihavtljiva so, gde je: R1, H, hidroksi ili metoksi; i R4 je H, -C(0)R9, -C(0)0R9, -C(0)NR9R10 ili hidroksi zaštitna grupa; i svaka R9 i R10 su nezavisno H ili C1-C6alkil.
31. Jedinjenje formule: ili njegova farmaceutski prihvatljiva so, gde je: R1, H. hidroksi ili metoksi; i R4 je H, -C(0)R9, -C(O)0R9, -C(O)KR9R10 ili hidroksi zaštitna grupa; i svaka R9 i R10 su nezavisno H ili C1-C6alkil.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4934897P | 1997-06-11 | 1997-06-11 | |
| PCT/IB1998/000839 WO1998056802A1 (en) | 1997-06-11 | 1998-05-29 | 4'-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME00876B true ME00876B (me) | 2012-06-20 |
Family
ID=21959336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-1999-586A ME00876B (me) | 1997-06-11 | 1998-05-29 | 4"supstituisani-9-deokso-9a-aza-9a-homoeritromicin a derivati |
Country Status (49)
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HN1998000086A (es) * | 1997-06-11 | 1999-03-08 | Pfizer Prod Inc | Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos. |
| US6339063B1 (en) | 1997-09-10 | 2002-01-15 | Merck & Co., Inc. | 9a-azalides as veterinary antimicrobial agents |
| EP1779853A3 (en) * | 1997-09-10 | 2010-01-27 | Merial Ltd. | 9a-azalides as veterinary antimicrobial agents |
| DK1011689T3 (da) * | 1997-09-10 | 2007-05-21 | Merial Ltd | Anvendelse af 9a-azalider som veterinære antimikrobielle midler |
| AP9801420A0 (en) * | 1998-01-02 | 1998-12-31 | Pfizer Prod Inc | Novel macrolides. |
| US6043227A (en) * | 1998-08-19 | 2000-03-28 | Pfizer Inc. | C11 carbamates of macrolide antibacterials |
| EP1437360A3 (en) * | 1998-08-19 | 2005-04-06 | Pfizer Products Inc. | C11 Carbamates of macrolide antibacterials |
| US6100240A (en) * | 1998-10-09 | 2000-08-08 | Pfizer Inc | Macrolide derivatives |
| CA2292359C (en) * | 1999-01-28 | 2004-09-28 | Pfizer Products Inc. | Novel azalides and methods of making same |
| KR100474229B1 (ko) * | 1999-05-18 | 2005-03-08 | 화이자 프로덕츠 인크. | 마크롤라이드계 항생제의 신규 결정형 |
| HK1045523A1 (zh) * | 1999-05-24 | 2002-11-29 | 辉瑞产品公司 | 13-甲基红霉素衍生物 |
| US6465437B1 (en) * | 1999-06-30 | 2002-10-15 | Pfizer Inc. | Diphosphate salt of a 4″-substituted-9-deoxo-9A-AZA-9A- homoerythromycin derivative and its pharmaceutical composition |
| BR0009101A (pt) * | 1999-08-24 | 2002-02-05 | Abbott Lab | 9a-azalidas com atividade antibacteriana |
| US6764996B1 (en) | 1999-08-24 | 2004-07-20 | Abbott Laboratories | 9a-azalides with antibacterial activity |
| US6608033B1 (en) * | 1999-08-27 | 2003-08-19 | Pfizer Inc. | Treatment or prevention of coccidiosis |
| AU779748C (en) * | 2000-01-27 | 2005-12-08 | Zoetis Services Llc | Azalide antibiotic compositions |
| HUP0300585A3 (en) * | 2000-04-27 | 2003-09-29 | Pfizer Prod Inc | Process for the use of azalide antibiotic compositions for treating or preventing a bacterial or protozoal infection in mammals |
| CN1297564C (zh) * | 2001-04-27 | 2007-01-31 | 辉瑞产品公司 | 4″－取代－9－脱氧－9a－氮杂－9a－高红霉素A衍生物的制备方法 |
| WO2003011266A2 (en) * | 2001-08-01 | 2003-02-13 | Pfizer Products Inc. | Azalide antibiotic compositions |
| EP1638549A4 (en) | 2003-03-10 | 2011-06-15 | Optimer Pharmaceuticals Inc | NEW ANTIBACTERIAL AGENTS |
| US7276487B2 (en) | 2003-09-23 | 2007-10-02 | Enanta Pharmaceuticals, Inc. | 9a, 11-3C-bicyclic 9a-azalide derivatives |
| EP1689434A1 (en) * | 2003-11-21 | 2006-08-16 | Pfizer Products Inc. | The use of anti biotics as vaccine adjuvants |
| CN103030617A (zh) * | 2004-03-16 | 2013-04-10 | 贝林格尔.英格海姆国际有限公司 | 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法 |
| US20060116336A1 (en) * | 2004-03-17 | 2006-06-01 | American Pharmaceutical Partners, Inc. | Lyophilized azithromycin formulation |
| US7468428B2 (en) * | 2004-03-17 | 2008-12-23 | App Pharmaceuticals, Llc | Lyophilized azithromycin formulation |
| US7402568B2 (en) | 2004-09-29 | 2008-07-22 | Enanta Pharmaceuticals, Inc. | Bicyclic 9a-azalide derivatives |
| US7767797B1 (en) * | 2004-09-30 | 2010-08-03 | Synovo Gmbh | Macrocyclic compounds and methods of use thereof |
| US7271155B2 (en) | 2005-01-07 | 2007-09-18 | Enanta Pharmaceuticals, Inc. | 9A, 11-2C-bicyclic 9a-azalide derivatives |
| DE602006006546D1 (de) * | 2005-01-14 | 2009-06-10 | Glaxosmithkline Zagreb | 9a-carbamoyl- und thiocarbamoylazalide mit antimalariawirkung |
| US9453042B2 (en) * | 2007-10-25 | 2016-09-27 | Cempra Pharmaceuticals, Inc. | Process for the preparation of macrolide antibacterial agents |
| HRP20160222T1 (hr) | 2008-10-24 | 2016-04-08 | Cempra Pharmaceuticals, Inc. | Biozaštite uporabom makrolida koji sadrže triazol |
| US9937194B1 (en) * | 2009-06-12 | 2018-04-10 | Cempra Pharmaceuticals, Inc. | Compounds and methods for treating inflammatory diseases |
| EP2475253B1 (en) | 2009-09-10 | 2016-10-26 | Cempra Pharmaceuticals, Inc. | Methods for treating malaria, tuberculosis and mac diseases |
| JP5711352B2 (ja) | 2010-03-22 | 2015-04-30 | センプラ ファーマシューティカルズ，インコーポレイテッド | マクロライドの結晶形、およびその使用 |
| CN102917708B (zh) | 2010-05-20 | 2015-11-25 | 森普拉制药公司 | 制备大环内酯和酮内酯及其中间体的方法 |
| US9815863B2 (en) | 2010-09-10 | 2017-11-14 | Cempra Pharmaceuticals, Inc. | Hydrogen bond forming fluoro ketolides for treating diseases |
| WO2012038372A1 (en) | 2010-09-20 | 2012-03-29 | Novartis Ag | Novel process for the preparation of 9-deoxo-9a-aza- 9a-homoerythromycin a modified in the c-4'' of the cladinose ring by an epoxide group |
| WO2012051126A2 (en) * | 2010-10-10 | 2012-04-19 | Synovo Gmbh | Anti-inflammatory macrolides |
| CN102993250B (zh) * | 2011-07-06 | 2016-02-10 | 洛阳惠中兽药有限公司 | C-3取代的-9-脱氧-9a-氮杂-9a-高红霉素a衍生物 |
| CN102260306B (zh) * | 2011-07-22 | 2012-07-18 | 山东鲁抗舍里乐药业有限公司 | 一种制备泰拉霉素的方法 |
| EP2736915A1 (en) | 2011-07-27 | 2014-06-04 | Farma GRS, d.o.o. | New crystalline forms of tulathromycin |
| IN2014DN08939A (me) | 2012-03-27 | 2015-05-22 | Cempra Pharmaceuticals Inc | |
| CN102786569B (zh) * | 2012-09-07 | 2016-12-07 | 安徽中升药业有限公司 | 泰拉霉素中间体及其制备方法与泰拉霉素的制备方法 |
| CA2905975A1 (en) | 2013-03-14 | 2014-09-25 | Cempra Pharmaceuticals, Inc. | Methods for treating respiratory diseases and formulations therefor |
| EP2968384A4 (en) | 2013-03-15 | 2017-02-15 | Cempra Pharmaceuticals, Inc. | Convergent processes for preparing macrolide antibacterial agents |
| SI3027634T1 (sl) * | 2013-07-31 | 2018-10-30 | Farma Grs, D.O.O. | Proces za pripravo tulatromicina |
| CN103497227B (zh) * | 2013-09-13 | 2015-09-30 | 青岛科技大学 | 一种泰拉菌素中间体的制备方法 |
| CN104725446B (zh) * | 2015-03-26 | 2017-10-27 | 宁夏泰瑞制药股份有限公司 | 一种从泰拉霉素粗品中分离泰拉霉素a和泰拉霉素b的方法 |
| CN104861018A (zh) * | 2015-06-17 | 2015-08-26 | 瑞普（天津）生物药业有限公司 | 一种泰拉菌素的制备方法 |
| CN105646617A (zh) * | 2016-01-21 | 2016-06-08 | 杭州海尔希畜牧科技有限公司 | 一种制备泰拉霉素的方法 |
| FR3048612B1 (fr) * | 2016-03-14 | 2020-10-02 | Septeos | Tulathromycine potentialisee |
| CN106046077B (zh) * | 2016-08-04 | 2019-07-26 | 湖北美天生物科技股份有限公司 | 一种泰拉霉素a的合成方法 |
| CN108003207B (zh) * | 2017-12-19 | 2019-05-10 | 海门慧聚药业有限公司 | 制备泰拉霉素的方法 |
| CN111087433B (zh) * | 2018-10-23 | 2023-03-21 | 湖北美天生物科技股份有限公司 | 一种泰拉霉素中间体的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU43006B (en) * | 1981-03-06 | 1989-02-28 | Pliva Pharm & Chem Works | Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof |
| US4474768A (en) * | 1982-07-19 | 1984-10-02 | Pfizer Inc. | N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor |
| US4512982A (en) | 1984-04-13 | 1985-04-23 | Pfizer Inc. | 9α-Aza-9α-homoerythromycin compounds, pharmaceutical composition and therapeutic method |
| CA2064634C (en) * | 1991-04-04 | 1998-08-04 | James V. Heck | 9-deoxo-8a-aza-8a-homoerythromycin a derivatives modified at the 4"- and8a-positions |
| US5226958A (en) * | 1991-04-11 | 1993-07-13 | Pacemark, Inc. | Sealant for pneumatic inner tubes and tubeless tires |
| EP0549040A1 (en) | 1991-12-20 | 1993-06-30 | Merck & Co. Inc. | Methods of making 4" derivatives of 9-deoxo-8a-aza-8a-alkyl-8a-homoerythromycin A |
| US5441939A (en) * | 1994-03-04 | 1995-08-15 | Pfizer Inc. | 3"-desmethoxy derivatives of erythromycin and azithromycin |
| HN1998000086A (es) | 1997-06-11 | 1999-03-08 | Pfizer Prod Inc | Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos. |
| UA70972C2 (uk) | 1998-11-20 | 2004-11-15 | Пфайзер Продактс Інк. | 13-членні азаліди і їх застосування як антибіотиків |
-
1998
- 1998-05-03 HN HN1998000086A patent/HN1998000086A/es unknown
- 1998-05-27 PA PA19988452201A patent/PA8452201A1/es unknown
- 1998-05-29 KR KR10-1999-7011642A patent/KR100396168B1/ko not_active Expired - Lifetime
- 1998-05-29 AT AT98920693T patent/ATE251173T1/de active
- 1998-05-29 SK SK1683-99A patent/SK284171B6/sk not_active IP Right Cessation
- 1998-05-29 CN CN2006100513455A patent/CN1793155B/zh not_active Expired - Lifetime
- 1998-05-29 NZ NZ514871A patent/NZ514871A/en not_active IP Right Cessation
- 1998-05-29 CZ CZ0442199A patent/CZ298556B6/cs not_active IP Right Cessation
- 1998-05-29 EA EA199901015A patent/EA002441B1/ru not_active IP Right Cessation
- 1998-05-29 JP JP50193599A patent/JP3315704B2/ja not_active Expired - Lifetime
- 1998-05-29 UA UA99126736A patent/UA67744C2/uk unknown
- 1998-05-29 SI SI9830572T patent/SI0988310T1/xx unknown
- 1998-05-29 CN CNB2004100491122A patent/CN1243766C/zh not_active Expired - Lifetime
- 1998-05-29 DE DE122004000018C patent/DE122004000018I2/de active Active
- 1998-05-29 DE DE69818665T patent/DE69818665T2/de not_active Expired - Lifetime
- 1998-05-29 WO PCT/IB1998/000839 patent/WO1998056802A1/en not_active Ceased
- 1998-05-29 BR BRPI9810519A patent/BRPI9810519B8/pt not_active IP Right Cessation
- 1998-05-29 ME MEP-1999-586A patent/ME00876B/me unknown
- 1998-05-29 CN CN200910145318A patent/CN101691390A/zh active Pending
- 1998-05-29 DK DK98920693T patent/DK0988310T3/da active
- 1998-05-29 CN CNB988059223A patent/CN1172947C/zh not_active Expired - Lifetime
- 1998-05-29 EP EP98920693A patent/EP0988310B9/en not_active Expired - Lifetime
- 1998-05-29 PT PT98920693T patent/PT988310E/pt unknown
- 1998-05-29 AU AU73475/98A patent/AU749816B2/en not_active Expired
- 1998-05-29 US US09/424,104 patent/US6420536B1/en not_active Expired - Lifetime
- 1998-05-29 HU HU0002209A patent/HU228005B1/hu active Protection Beyond IP Right Term
- 1998-05-29 IL IL13280998A patent/IL132809A0/xx not_active IP Right Cessation
- 1998-05-29 NZ NZ500660A patent/NZ500660A/en not_active IP Right Cessation
- 1998-05-29 CA CA002293823A patent/CA2293823C/en not_active Expired - Lifetime
- 1998-05-29 ES ES98920693T patent/ES2205487T3/es not_active Expired - Lifetime
- 1998-05-29 PL PL337505A patent/PL191601B1/pl unknown
- 1998-05-29 ID IDW991569A patent/ID22992A/id unknown
- 1998-05-29 RS YUP-586/99A patent/RS49675B/sr unknown
- 1998-06-04 AP APAP/P/1998/001255A patent/AP1231A/en active
- 1998-06-08 PE PE1998000471A patent/PE79699A1/es not_active Application Discontinuation
- 1998-06-09 EG EG64098A patent/EG24081A/xx active
- 1998-06-09 AR ARP980102706A patent/AR013086A1/es active IP Right Grant
- 1998-06-09 MY MYPI98002575A patent/MY123354A/en unknown
- 1998-06-10 ZA ZA9805017A patent/ZA985017B/xx unknown
- 1998-06-10 GT GT199800077A patent/GT199800077A/es unknown
- 1998-06-10 TN TNTNSN98082A patent/TNSN98082A1/fr unknown
- 1998-06-10 DZ DZ980124A patent/DZ2514A1/xx active
- 1998-06-10 CO CO98033232A patent/CO4950611A1/es unknown
- 1998-06-10 MA MA25107A patent/MA24564A1/fr unknown
- 1998-06-11 HR HR980314A patent/HRP980314B1/xx not_active IP Right Cessation
- 1998-06-11 UY UY25040A patent/UY25040A1/es not_active IP Right Cessation
-
1999
- 1999-02-26 TW TW087109077A patent/TW472060B/zh not_active IP Right Cessation
- 1999-11-16 IS IS5252A patent/IS1998B/is unknown
- 1999-12-03 OA OA9900268A patent/OA11224A/en unknown
- 1999-12-03 BG BG103945A patent/BG64391B1/bg unknown
- 1999-12-10 NO NO996106A patent/NO316911B1/no not_active IP Right Cessation
-
2001
- 2001-11-21 US US09/989,936 patent/US20020061858A1/en not_active Abandoned
-
2002
- 2002-03-13 JP JP2002068432A patent/JP2002316933A/ja active Pending
- 2002-10-18 US US10/273,879 patent/US6777393B2/en not_active Expired - Lifetime
-
2004
- 2004-03-26 US US10/810,922 patent/US6936592B2/en not_active Expired - Lifetime
- 2004-05-04 FR FR04C0013C patent/FR04C0013I2/fr active Active
- 2004-05-05 LU LU91076C patent/LU91076I9/fr unknown
- 2004-05-10 NL NL300150C patent/NL300150I2/nl unknown
-
2012
- 2012-11-26 HU HUS1200028C patent/HUS1200028I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME00876B (me) | 4"supstituisani-9-deokso-9a-aza-9a-homoeritromicin a derivati | |
| DK446279A (da) | Fremgangsmaade til fremstilling af substituerede 1-carba-2-penem-3-carboxylsyrer | |
| YU47099B (sh) | Postupak za dobijanje makrolidnih jedinjenja | |
| BR9910971A (pt) | Composto, processos para a preparação de um composto e para produzir um efeito antibacteriano em um animal de sangue quente, uso de um composto, e, composição farmacêutica | |
| KR840005448A (ko) | 티에노〔3, 2-c〕 피리딘 유도체의 제조방법 | |
| SE8106642L (sv) | Piperazinylbensoheterocykliska foreningar och forfarande for framstellning derav | |
| ATE14423T1 (de) | Hydroxamsaeurederivate vom typ der mannich-basen mit verbesserter biologischer verfuegbarkeit von nicht-steroiden entzuendungshemmern, verfahren zur herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzung. | |
| AR013085A1 (es) | Compuestos derivados de macrolidos c-4'' sustituidos, composicion farmaceutica, metodo de preparacion, compuestos intermediarios para su preparacion | |
| HUP0302526A2 (hu) | Makrolid vegyületek, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
| AR059523A2 (es) | Azalidas de 13 miembros macrolidos, composiciones farmaceuticas, su uso en la preparacion de medicamentos para el tratamiento de infecciones y procedimientos para preparar estos compuestos. | |
| ATE96772T1 (de) | Substituierte 2-alkinylphenole mit entzuendungshemmender wirkung, verfahren zu deren herstellung und pharmazeutische zusammensetzungen. | |
| DK601683A (da) | Dialkylaminoalkoxybenzylalkoholderivater | |
| ATE18221T1 (de) | (1-arylcyclobutyl)(heterocyclyl)methylaminderivate, ihre herstellung und ihre verwendung als arzneimittel. | |
| SE8005686L (sv) | Nya halogenvinkamonderivat jemte sett for deras framstellning | |
| JPS5283396A (en) | Novel compound physiologically acceptable salts thereof process for preparing same and medical composition containing same | |
| GB1421446A (en) | Disalkylamino esters of benzopyranopyridines and compositions containing the same | |
| ATE445589T1 (de) | Neue retinoidderivate und eine pharmazeutische anti-krebs-zusammensetzung, die diese verbindungen enthält | |
| OA09372A (fr) | "Nouvelles acyl benzoxazolinones, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent". | |
| ATE16278T1 (de) | Hydroxybenzylamino-aryl verbindungen, verfahren zur deren herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen. | |
| NO150316C (no) | Analogifremgangsmaate ved fremstilling av terapeutisk aktive nitrosoureaderivater | |
| NO180475C (no) | Fremgangsmåte for fremstilling av et farmasöytisk preparat | |
| SE8005687L (sv) | Nya 10-halogen-e-homoeburnaner jemte sett for deras framstellning | |
| SE8103983L (sv) | Heterocykliska foreningar, deras framstellning och farmaceutiska kompositioner innehallande dessa | |
| ES8401056A1 (es) | "procedimiento para la fabricacion de derivados de la quinolina". | |
| RU98113854A (ru) | Эфирные производные транс-аповинкаминовой кислоты в качестве лекарственных средств |